Table 1.
Patient characteristics
| AML | Myeloid Neoplasms (Non-AML) | |
|---|---|---|
| Total | 51 | 7 |
| Subtype (%) | AML with recurrent | MDS-MLD: 2 |
| genetic abnormalities: 20 (39) | MDS-EB-2: 1 | |
| AML-MRC: 22 (43) | CMML-2: 1 | |
| t-AML: 4 (8) | MDS/MPN: 2 | |
| AML, NOS: 5 (10) | CNL: 1 | |
| Age (years; median and range) | 63 (20–86) | 69 (42–84) |
| Sex | ||
| Male | 25 | 4 |
| Female | 26 | 3 |
| EZH2-mutated patients (%) | 6 (12) | 7 (100) |
| Mutations per patient (median and range) | 3 (0–7) | 4 (3–7) |
| Del(7q) or -7 (%) | 13 (25) | 2 (29) |
| WBC (× 109/L; median and range) | 10.4 (0.6–192.6) | 18.4 (1.6–126.5) |
| BM blasts (%; median and range) | 63 (10–100) | 4 (1–16) |
| Treatment | ||
| Induction chemotherapy (%) | 31 (61) | 0 |
| HSCT (%) | 27 (53) | 4 (57) |
| Non-intensive therapy (%) | 13 (25) | 3 (43) |
AML-MRC acute myeloid leukemia with myelodysplasia-related changes, BM bone marrow, CMML chronic myelomonocytic leukemia, CNL chronic neutrophilic leukemia, HSCT hematopoietic stem cell transplantation, MDS-EB myelodysplastic syndrome with excess blasts, MDS-MLD MDS with multilineage dysplasia, MPN myeloproliferative neoplasm, NOS not otherwise specified, WBC white blood cells, t-AML therapy-related AML